Zacks: Brokerages Anticipate TherapeuticsMD Inc (TXMD) Will Post Quarterly Sales of $4.59 Million

Wall Street brokerages expect that TherapeuticsMD Inc (NASDAQ:TXMD) will announce $4.59 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for TherapeuticsMD’s earnings, with the highest sales estimate coming in at $5.09 million and the lowest estimate coming in at $4.22 million. TherapeuticsMD posted sales of $4.42 million in the same quarter last year, which suggests a positive year over year growth rate of 3.8%. The firm is scheduled to announce its next earnings report on Monday, November 5th.

On average, analysts expect that TherapeuticsMD will report full year sales of $19.06 million for the current financial year, with estimates ranging from $17.47 million to $20.70 million. For the next fiscal year, analysts expect that the firm will report sales of $128.64 million, with estimates ranging from $74.00 million to $180.20 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, July 30th. The company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03). The company had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. TherapeuticsMD’s revenue for the quarter was down 11.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.10) earnings per share.

Several equities analysts recently weighed in on TXMD shares. Zacks Investment Research downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday, August 17th. Oppenheimer set a $14.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, September 5th. Cantor Fitzgerald lifted their target price on TherapeuticsMD from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Tuesday, August 14th. ValuEngine upgraded TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Friday, September 21st. Finally, BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 29th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $15.40.

In other news, CEO Robert G. Finizio sold 184,000 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $6.24, for a total value of $1,148,160.00. Following the transaction, the chief executive officer now directly owns 18,485,559 shares in the company, valued at $115,349,888.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C.K. Iv Milligan sold 250,000 shares of the business’s stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $6.10, for a total value of $1,525,000.00. Following the completion of the transaction, the insider now owns 1,597,419 shares in the company, valued at $9,744,255.90. The disclosure for this sale can be found here. Insiders sold 1,450,000 shares of company stock worth $9,101,374 over the last 90 days. Company insiders own 22.85% of the company’s stock.

Several institutional investors have recently made changes to their positions in TXMD. Public Employees Retirement Association of Colorado lifted its position in shares of TherapeuticsMD by 2,545.7% in the second quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock valued at $6,686,000 after acquiring an additional 1,031,000 shares in the last quarter. BlackRock Inc. lifted its position in shares of TherapeuticsMD by 4.4% in the second quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after acquiring an additional 608,470 shares in the last quarter. OppenheimerFunds Inc. lifted its position in shares of TherapeuticsMD by 17.4% in the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after acquiring an additional 286,123 shares in the last quarter. Voya Investment Management LLC lifted its position in shares of TherapeuticsMD by 7.7% in the second quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock valued at $21,336,000 after acquiring an additional 242,995 shares in the last quarter. Finally, Raymond James & Associates lifted its position in shares of TherapeuticsMD by 26.6% in the second quarter. Raymond James & Associates now owns 719,568 shares of the company’s stock valued at $4,490,000 after acquiring an additional 151,335 shares in the last quarter. Institutional investors and hedge funds own 66.14% of the company’s stock.

NASDAQ TXMD traded down $0.17 on Friday, hitting $5.42. 3,180,026 shares of the company traded hands, compared to its average volume of 2,525,105. The company has a market capitalization of $1.52 billion, a PE ratio of -14.65 and a beta of 1.40. The company has a debt-to-equity ratio of 0.94, a quick ratio of 7.79 and a current ratio of 7.88. TherapeuticsMD has a 52-week low of $4.34 and a 52-week high of $7.66.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Article: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply